C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics, Inc. (CCCC) is a healthcare company (biotechnology) based in the United States. The share price is $2.54, down 4.34% on the day, which values the company at $332.89M. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$2.54−4.34% today
Market value
$332.89M
Funk Score
35/100
Against its own history
Well below its usual priceusual price $3.77
200-week average
$3.7432% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

C4 Therapeutics, Inc. in more detail

CCCC trades at -2.9× next year's expected earnings, 10.3× sales. Measured against its own history, the price is 33% below what its usual multiples would imply ($3.77) — well below its usual price. It sits 32% below its 200-week average of $3.74.

Its Funk Score is 35 out of 100 (financial strength 5.0, profitability 0.0, growth 4.2, value 4.6, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Share count keeps rising.

1 of the superinvestors tracked here hold CCCC, including Peter Kolchinsky (0.3% of the portfolio).

Superinvestors holding CCCC

1 of the investors tracked here report a position in their latest 13F filing.

C4 Therapeutics, Inc. (CCCC): questions and answers

What is C4 Therapeutics, Inc.'s market cap?

C4 Therapeutics, Inc. is valued at $332.89M at a share price of $2.54.

Is CCCC overvalued or undervalued?

Against its own history, CCCC is well below its usual price: the price is 33% below the $3.77 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is CCCC above its 200-week moving average?

No. CCCC is 32.3% below its 200-week average of $3.74. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is C4 Therapeutics, Inc. growing?

Over the last three fiscal years C4 Therapeutics, Inc.'s revenue grew 5.0% a year.

Does CCCC pay a dividend?

C4 Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own CCCC?

In their latest quarterly filings, Peter Kolchinsky (0.3% of the portfolio) hold CCCC. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “C4 Therapeutics, Inc. (CCCC) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/CCCC

Underlying data: Yahoo Finance; company filings with the SEC.